Acquisition by Cittadine Andrew of 12000 shares of Monopar Therapeutics at 0.6443 subject to Rule 16b-3

MNPR Stock  USD 22.05  1.95  8.12%   
Slightly above 71 percent of all Monopar Therapeutics' retail investors are curious in acquiring. The analysis of the overall investor sentiment regarding Monopar Therapeutics suggests that quite a few traders are confidant. Monopar Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Monopar Therapeutics. Many technical investors use Monopar Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Monopar Therapeutics Officer Chief Operating Officer. Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Acquisition of 12000 common stock at 0.6443 of Monopar Therapeutics by Cittadine Andrew on 3rd of September 2024. This event was filed by Monopar Therapeutics with SEC on 2024-05-31. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Monopar Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Monopar Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Monopar Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Monopar Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Monopar Therapeutics Fundamental Analysis

We analyze Monopar Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Monopar Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Monopar Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Price To Earning

Price To Earning Comparative Analysis

Monopar Therapeutics is currently under evaluation in price to earning category among its peers. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

Monopar Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Monopar Therapeutics stock to make a market-neutral strategy. Peer analysis of Monopar Therapeutics could also be used in its relative valuation, which is a method of valuing Monopar Therapeutics by comparing valuation metrics with similar companies.

Peers

Monopar Therapeutics Related Equities

ANEBAnebulo Pharmaceuticals   29.60   
0%
100.0%
ACXPAcurx Pharmaceuticals   6.02   
0%
20.0%
PEPGPepGen   3.60   
0%
12.0%
MLYSMineralys Therapeutics,   2.43   
0%
8.0%
CADLCandel Therapeutics   1.97   
0%
6.0%
AVTEAerovate Therapeutics   1.56   
0%
5.0%
SCPHScpharmaceuticals   0.29   
1.0%
0%
RZLTRezolute   0.68   
2.0%
0%
MOLNMolecular Partners   2.39   
8.0%
0%
PMVPPmv Pharmaceuticals   2.65   
8.0%
0%
ANTXAN2 Therapeutics   2.86   
9.0%
0%
KTTAPasithea Therapeutics   3.01   
10.0%
0%
PHVSPharvaris   3.27   
11.0%
0%
ADAGAdagene   5.37   
18.0%
0%
ACRVAcrivon Therapeutics,   8.64   
29.0%
0%
DMACDiaMedica Therapeutics   17.94   
60.0%
0%

Additional Tools for Monopar Stock Analysis

When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.